City of Hope Appoints Dr. Christine M. Lovly to Lead National Thoracic Oncology Program City of Hope has announced the appointment of physician-scientist Christine M. Lovly, M.D., Ph.D., F.A.S.C.O., as the head of its new National Thoracic Oncology Program, effective…
Phase III ALLEGORY trial achieved its primary and all key secondary endpoints with Gazyva, an anti-CD20 monoclonal antibody engineered to enhance B cell depletion. – Gazyva shows potential to become a transformative new standard of care for up to 3.4…
Enigma Biomedical USA Announces FDA Acceptance of New Drug Application for Tau PET Radiodiagnostic MK-6240 in Alzheimer’s Diseas Biomedical USA (EB USA) today announced that the U.S. Food and Drug Administration (FDA) has formally accepted the New Drug Application (NDA)…
Ferring Showcases New Real-World Evidence on ADSTILADRIN® at the 101st Western Section AUA Annual Meeting Napa, CA — October 29, 2025 — Ferring Pharmaceuticals today announced that three abstracts highlighting new real-world data for ADSTILADRIN® (nadofaragene firadenovec-vncg) will be presented…
Ferrer Completes Patient Enrollment for the PROSPER Phase II Clinical Trial in Progressive Supranuclear Palsy Ahead of Schedule Barcelona, Spain — [October 2025] — Ferrer, the international pharmaceutical company headquartered in Spain, today announced the successful completion of patient recruitment…
Iambic Therapeutics and Jazz Pharmaceuticals Announce Research Collaboration to Evaluate IAM1363 and Zanidatamab Combination in HER2-Positive Breast Cancer SAN DIEGO, Calif., October 22, 2025 – Iambic Therapeutics, a clinical-stage life science and technology company pioneering the use of artificial intelligence…
Enamine Plays Key Role in Discovery of Promising Broad-Spectrum Coronavirus Antiviral Enamine, a leading chemistry and R&D services company, has announced its pivotal contribution to the discovery of a promising broad-spectrum coronavirus antiviral pre-clinical candidate. This milestone was achieved through…
Bayer to Present Late-Breaking OCEANIC-STROKE Data at World Stroke Congress 2025 Bayer will present methods and baseline characteristic data from its global Phase III OCEANIC-STROKE study in a late-breaking presentation at the 17th World Stroke Congress (WSC 2025). The Congress…
a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today presents on the positive interim efficacy data from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC) at the annual European Society…
a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data presented at IDWeek 2025™ in Atlanta, Ga., by researchers from Columbia University Irving Medical Center show metagenomic sequencing that detects both RNA and DNA pathogens, available through Delve…